Immatics stock rises on cell therapy program collaboration with Bristol Myers
seekingalpha.com
finance
2022-06-02 13:23:43

Drew Angerer/Getty Images News Immatics (NASDAQ:IMTX) expanded its collaboration with Bristol Myers Squibb (NYSE:BMY) to develop multiple allogeneic off-the-shelf TCR-T and/or CAR-T programs. Under the agreement, Immatics will receive $60M upfront and up to $700M per program by Bristol Myers via development, regulatory and sales milestone payments plus royalties. Germany-based Immatics said in a June 2 release that the two companies will develop two programs owned by Bristol Myers and both companies have an option to develop up to four additional programs each.
